New book by Larry Connors Click here Improve your trading - See how
BusinessNetWire is an affiliate of Stock Profiler.US, LLC. Stock Profiler's website has been upgraded with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact us at (603) 424-4420.
-------------------------------------------
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) closed at $0.15 Tuesday, trading 6,705 shares.
Company News- July 16, 2008: Infinity Medical Group Inc. Announces Distribution of N.V. Perricone M.D. Cosmeceuticals
Infinity Medical Group Inc. (PINKSHEETS: IMGR), a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics that offer elective medical and dental procedures, is pleased to have announced earlier today that through its partner Rejuvena Medspa, Rejuvena Skin and Laser Centre is proud to be a Canadian distributor for N.V. Perricone M.D. Cosmeceuticals. 2,000 Americans will turn 50 every day (1 every 8 seconds) for the next 20 years. Studies show the number of Americans over 55 will grow by 60% in the next 20 years and their buying power will exceed $2 trillion by 2007.
Americans spent just under $9.4 billion on cosmetic medical procedures in 2003. In 2004, American consumers spent $44.6 billion on anti-aging products and services, and the total anti-aging market is projected to reach $72 billion by 2009. (Business Communications Co. Inc. February 2005) Infinity Medical Group Inc. is a specialty healthcare development company whose primary focus is in servicing the cosmetic medical laser and dental implant fields. Infinity Medical Group provides turnkey support for both medical and dental professionals and aids in their professional development through the emerging fields of cosmetic medical lasers and dental implants. Infinity differentiates itself by offering "a hands-on approach to finance, building, systemization, branding, containment, training and development of its group of clinics." "We are excited to announce that the entire N.V. Perricone line is available directly through Rejuvena. Dr. Perricone is the focus of a series of award-wining television specials airing in the U.S. on PBS TV. He is a popular guest on American television, appearing on the Today Show, Oprah, Larry King, 20/20, Good Morning America, The View, CNN, Fox, Extra, Access Hollywood as well as many other news and lifestyle broadcasts. He has been featured in the New York Times, Wall Street Journal, Vogue, Harper's Bazaar, W, Forbes, People, WWD, USA Today and a host of other major magazines and newspapers around the globe. Vogue named Dr. Perricone one of the best dermatologists in the U.S. in 2001 -- and the opening of the Perricone Flagship store on Madison Avenue (NYC) was named one of the 'Top Ten Beauty Stories' by WWD in 2005," said Stefan Kim, CEO, Infinity Medical Group.
About Infinity Medical Group Inc.: Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics offering elective procedures.
-------------------------------------------
digiMedical Solutions, Inc. (PINKSHEETS: DGMS | Quote | Chart | News | PowerRating) closed at $0.02 Tuesday, trading 100,000 shares.
Company News- July 16, 2008: digiMedical Solutions, Inc. Continues to Expand Sales in South Florida by Providing .Net-Based Digital Prescription Software and Call Center Services for Dr. Jennifer Bevins
digiMedical Solutions, Inc. (PINKSHEETS: DGMS | Quote | Chart | News | PowerRating) announced earlier today that the Company has signed a contract with Dr. Jennifer Bevins of Southwest Florida Women's Group, P.A. in Naples, Florida to implement the Company's .Net-based digital prescription handling software, digiRX and digiReauth, and to supply call center services to support the reauthorization of prescriptions. Southwest Women's Group is a multi-physician practice providing obstetrical and gynecological services. Dr. Bevins graduated from the University of Miami in 1999 and completed her residency at Tampa General Hospital. She has been in practice for five years and recently joined the Southwest Florida Women's Group.
Earlier this year, digiMedical announced efforts to expand the Company's sales in Florida by signing contracts with doctors and clinics to implement the Company's proprietary digital prescription software and reauthorization call center services. Since launching those efforts, they have signed contracts with multiple doctors in Florida to include: Drs. Angela Marshall, Wendy Humphrey and Betsy Brothers also of Southwest Florida Women's Group, P.A., Dr. Daniel Kaplan, Dr. Moorthy of Pain Management Center of Naples, Dr. Shardul Nanavati, founder of Advanced Gastroenterology, Drs. Romero, Tineo and Seibert of Oaktree Family Practice, Orthopedic Surgeon Dr. Howard Kapp of Anchor Health Centers, Drs. Santos-Ocampo, Axline and Spilker of the Collier Heart Group, Dr. John Landi, the Medical Director of Vanish Vein and Laser Center and Dr. Wey of the Neuroscience and Spine Associates in Naples, Florida, among others.
digiMedical Prescription Handling Software digiMedical Solutions has operations in Texas and Florida and has built its own suite of proprietary software to handle prescriptions digitally from the physician's office to the pharmacy, securely and in compliance with all DEA and HIPAA requirements. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and digiAccounting.
Company Fact Sheet and Updates To be added to digiMedical's corporate e-mail list for shareholders and interested investors or to receive a Fact Sheet on the company, please send an e-mail to ir@digimedical.com.
About digiMedical Solutions, Inc.
digiMedical Solutions, Inc. (www.digimedical.com) is a pharmacy and medical technology company focused on developing next generation digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that will more closely align the doctor, pharmacist and patient. The company's planned growth will come from three channels: direct marketing of the company's wireless base d-prescription technology to doctors, acquisition of independent pharmacy chains and the sale of certain territories to "market partners" licensed to exploit the digiMedical Solutions model. digiMedical Solutions, Inc. currently owns and operates five (5) pharmacies located in Texas and Florida. digiMedical Solutions' unique business model brings doctor, patients and pharmacies into next generation medical technologies.
-------------------------------------------
Daxor Corporation (AMEX: DXR | Quote | Chart | News | PowerRating) closed at $16.30 Tuesday, trading 1,150 shares.
Company News- July 16, 2008: Daxor Announces International Publication of Clinical Study Involving Critically Ill Surgical Patients and Avoidance of Blood Transfusion Errors
Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, announced earlier today the June, 2008 publication of a clinical study in the Journal of Anesthesia and Analgesia titled, "Peripheral Blood Hematocrit in Critically Ill Surgical Patients: An Imprecise Surrogate of True Red Blood Cell Volume." The article reviews how transfusion errors may be avoided by including a blood volume measurement in critically ill surgical patients.
In this study involving 40 intensive care unit patients, red blood cell (RBC) volume was estimated by the conventional laboratory hematocrit measurement. Patients also underwent a direct blood volume measurement utilizing Daxor's Blood Volume Analyzer BVA-100. The resulting data from the BVA-100 demonstrated errors in the hematocrit measurement which significantly underestimated or overestimated the degree of a patient's RBC volume. These errors are particularly significant as the current approach to whether a patient does or does not receive a transfusion is largely guided by the hematocrit.
Clinicians in this study, conducted by the Division of Surgical Critical Care, Department of Surgery, University of Hawaii and The Queen's Medical Center of Honolulu, Hawaii, also included other commonly used variables and invasive hemodynamic data. Even with the inclusion of this additional data the patient's true RBC status was not recognized.
Given the shortages and approximate $200 cost of a RBC unit, and the fact that over $1.5 billion is spent annually on transfusions especially on complex critically ill surgical patients, management of which patient truly requires a transfusion is both a resource allocation and a vital clinical decision. A measured blood volume may well avoid treatment errors by inaccurate surrogate methods like the hematocrit.
Anesthesiology and Analgesia, a monthly international scientific journal for anesthesiology and critical care medicine physicians, also featured an editorial by Dr. Robert Hahn from the Clinical Research Center of Sdertlje, Sweden. Dr. Hahn commented in his editorial that, "Despite all controversies, the return of blood volume as a clinical parameter in the ICU would be most welcome." Dr. Hahn also highlighted the BVA-100's ability to provide capillary leak measurements, which he noted, "....may occasionally be even more interesting than the blood volume."
About Daxor Corporation
Daxor Corporation manufactures and markets the BVA-100, the only FDA-approved semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
-------------------------------------------
Given Imaging (NASDAQ: GIVN | Quote | Chart | News | PowerRating) (TELAVIV: GIVN | Quote | Chart | News | PowerRating) closed at $14.80 Tuesday, trading 17,100 shares.
Company News- July 16, 2008: Given Imaging to Host Second Quarter 2008 Financial Results Conference Calls
Given Imaging (NASDAQ: GIVN | Quote | Chart | News | PowerRating) (TELAVIV: GIVN), the global leader in capsule endoscopy, announced earlier today that the company will host conference calls on Thursday, August 7, 2008 to discuss second quarter 2008 financial results. The company plans to release results following the close of trading on Wednesday, August 6, 2008.
The company will host a conference call for English speakers on Thursday, August 7 at 9:00am ET. To participate in this teleconference, please dial 1-888-778-9069 fifteen minutes before the conference is scheduled to begin. Callers outside of the U.S. should dial 913-312-0849. The call will also be webcast live at www.givenimaging.com. A replay of the call will be available for two weeks on the company's website, or until August 21, 2008 by dialing 888-203-1112. Callers outside of the U.S. should dial 719-457-0820. The replay participant code is 5010408.
The company will host a separate conference call in Hebrew on August 7 at 14:00 Israel time (7:00am ET). To access this call, please dial +972-3-9180650 fifteen minutes before the conference is scheduled to begin. A replay of the call will be available August 10 - 12 by dialing +972-3-9255900.
About Given Imaging Ltd.
Given Imaging is redefining gastrointestinal diagnosis by developing, producing and marketing innovative, patient-friendly products for detecting gastrointestinal disorders. The company's technology platform is the PillCam Platform, featuring the PillCam video capsule, a disposable, miniature video camera contained in a capsule, which is ingested by the patient, a sensor array, data recorder and RAPID software. Given Imaging has a number of available capsules: the PillCam SB video capsule to visualize the entire small intestine which is currently marketed in the United States and in more than 60 other countries; the PillCam ESO video capsule to visualize the esophagus; the Agile patency capsule to determine the free passage of the PillCam capsule in the GI tract and the PillCam COLON video capsule to visualize the colon that has been cleared for marketing in the European Union. PillCam COLON has received a CE Mark, but is not cleared for marketing or available for commercial distribution in the USA. More than 700,000 patients worldwide have benefited from the PillCam capsule endoscopy procedure. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel. It has operating subsidiary companies in the United States, Germany, France, Japan, Australia and Singapore. Given Imaging's largest shareholders include Elron Electronic Industries (NASDAQ: ELRN) (TELAVIV: ELRN). For more information, visit http://www.givenimaging.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BusinessNetwire.US affiliates has not been compensated for services rendered; BusinessNetwire.US affiliates is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.businessnetwire.us) (disclaimers).
CONTACT: BusinessNetwire.US e-mail: info@ businessnetwire.us WWW: http://www.businessnetwire.us/
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
